PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

April 6, 2022

Stay up to date

Get the latest on cutting edge developments from our enterprises straight to your inbox